The author offers suggestions on how patients with cancer can maintain proper nutrition.

The risk of developing cancer from computed tomography (CT) scans appears to be significantly lower than previous estimates of 1.5% to 2% in the general population, conclude researchers.

The FDA today recommended to remove the breast-cancer indication from the label of Avastin (bevacizumab) after reviewing the results of four clinical studies.

Integrating single photon emission computerized tomography with computerized tomography to plan radiotherapy for breast-cancer patients may offer substantial protection against lymphedema.

Pregnant women who develop breast cancer should continue the pregnancy and be treated as closely as possible to standard recommendations for nonpregnant women.

Celecoxib (Celebrex) may ward off squamous and basal cell carcinomas in persons with extensive actinic damage who are at high risk for developing nonmelanoma skin cancers.

An investigational agent for the treatment of Hodgkin lymphoma has yielded very strong results in a phase II trial of heavily pretreated persons with relapsed or refractory disease.

Weightlifting may not increase lymphedema risk among breast-cancer survivors, according to results from a 1-year intervention among female survivors at risk for breast cancer-related lymphedema.

An easily derived score can indicate whether persons with cancer-associated thrombosis are at high or low risk of recurrent venous thromboembolism (VTE). Such information may help improve VTE-protective treatment for this at-risk population.

Mitoxantrone increased survival in children with relapsed acute lymphobastic leukemia (ALL) so significantly in a recent study that randomization to that agent or idarubicin was eventually stopped.